Search

Search Constraints

You searched for: Author/Creator van Kempen, Zoé L.E.

Search Results

1. Disease activity following pregnancy-related discontinuation of natalizumab in MS. Issue 1 (January 2018)

2. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. Issue 135 (February 2023)

4. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod. Issue 4 (6th July 2022)

5. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Issue 1 (January 2021)

6. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. (11th August 2020)

7. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. (9th November 2021)

8. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. (9th November 2021)